摘要
目的分析石家庄地区L-核苷类抗病毒药物耐药突变情况。方法对石家庄市第五医院就诊的慢性乙型肝炎患者119例进行乙型肝炎病毒逆转录酶区(HBV P区)基因序列测定。结果 119例患者HBV基因分型中B型5例(4.2%),C型114例(95.8%)。在B型中4例rtM204I突变;C型中73例rtM204I突变,40例rtM204V突变,1例rtM204I/V突变。119例存在204位点变异的慢性乙型肝炎患者中,共有9种突变模式,其中rtM204I单位点突变占总突变比例的23.5%(28/119),rtM204V单点突变占总突变比例的6%(7/119),rtL180M+rtM204I联合突变占总突变比例的22.7%(27/119),rtL180M+rtM204V联合突变占总突变比例的27.8%(33/119)。结论慢性乙型肝炎核苷类药物抗病毒治疗过程中,及时监测HBV P区基因耐药情况,尤其是出现rtM204I/V突变后,很容易联合其他位点突变。
Objective To analyze L-nucleoside antiviral drug resistance mutations in Shijiazhuang area.Methods One hundred and nineteen cases of chronic hepatitis B patients who visited in Shijiazhuang Fifth Hospital were diagnosed,and hepatitis B virus P region（HBV P） genes were equenced.Results Out of 119 patients,HBV genotype B accounted for 5 cases（4.2％）,C-type 114 cases（95.8％）.In type B,there were 4 cases with rtM204I mutation;C-type,there were 73 cases with rtM204I mutation,40 cases with rtM204V mutations,one case with rtM204I/V mutation.In 119 cases with chronic hepatitis B showing 204 point mutation,there were a total of nine kinds of mutation patterns,among which rtM204I single point mutation,rtL180M ＋rtM204VandrtL180M ＋rtM204I joint mutation proportion were 23.5％（28/119）,27.8％（33/119） and 22.7％ （27/119）,the sum of three percentage was 74.0％.Conclusion Chronic hepatitis B antiviral nucleoside drugs during treatment and timely monitoring of drug resistance in HBV P gene region,especially the emergence rtM204I / V mutation sites easily combined with other mutations.
出处
《临床荟萃》
CAS
2014年第10期1175-1177,共3页
Clinical Focus
基金
石家庄市科学技术研究与发展指导计划(131461093)
关键词
肝炎
乙型
慢性
L-核苷类似物
耐药
突变
hepatitis B, chronic
L-nucleoside analogs
resistance
mutations
